The share price of Leiden-based biotech firm Pharming almost halved on the Amsterdam stock exchange in early trading on Friday after the European medicines evaluation authority rejected an application by the company to allow it to market its new drug Rhucin.
The medicine, used to treat hereditary angioedema, is Pharming’s most important product. The company says it will appeal against the decision.
Thank you for donating to DutchNews.nl.
We could not provide the Dutch News service, and keep it free of charge, without the generous support of our readers. Your donations allow us to report on issues you tell us matter, and provide you with a summary of the most important Dutch news each day.Make a donation